Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
09/06/2025 12:19
June 9 (Reuters) - Formosa Pharmaceuticals Inc 6838.TW: HARROW ACQUIRES U.S. COMMERCIAL RIGHTS TO BYQLOVI™ (CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION) 0.05% FROM FORMOSA PHARMACEUTICALS HARROW: HARROW BUYS EXCLUSIVE U.S. COMMERCIAL RIGHTS FOR BYQLOVI HARROW- BYQLOVI EXPECTED TO BE AVAILABLE IN Q4 2025 Source text: ID:nPnbylNyJa Further company coverage: 6838.TW ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formosa Pharmaceuticals
See all newsBrief: Formosa Pharmaceuticals Announces Licensing Agreement With Rxilient
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%